These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31826897)

  • 21. The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis.
    Luo X; Du X; Huang L; Guo Q; Tan R; Zhou Y; Li Z; Xue X; Li T; Le K; Qian F; Chow SC; Yang Y
    Lancet Reg Health West Pac; 2023 Mar; 32():100670. PubMed ID: 36785854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.
    Villa F; Tutone M; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G; Jommi C
    Health Policy; 2019 Jun; 123(6):595-600. PubMed ID: 31097207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives.
    Hernandez I; Cousin EM; Wouters OJ; Gabriel N; Cameron T; Sullivan SD
    J Manag Care Spec Pharm; 2024 Aug; 30(8):762-772. PubMed ID: 38905356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility.
    Jung JH; Kim DJ; Suh K; You J; Lee JH; Joung KI; Suh DC
    Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33466893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China.
    Ling K; Qin H; Feng Y; Che H; Ding J; Li W
    Front Public Health; 2022; 10():1062736. PubMed ID: 36504948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Launch Price and Clinical Value With Reimbursement Decisions for Anticancer Drugs in China.
    Zhou J; Lu H; Pan J
    Int J Health Policy Manag; 2024; 13():8150. PubMed ID: 38618837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region.
    Salmasi S; Lee KS; Ming LC; Neoh CF; Elrggal ME; Babar ZD; Khan TM; Hadi MA
    BMC Cancer; 2017 Dec; 17(1):903. PubMed ID: 29282008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.
    Tay-Teo K; Ilbawi A; Hill SR
    JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linking the Price of Cancer Drug Treatments to Their Clinical Value.
    Gozzo L; Navarria A; Drago V; Longo L; Mansueto S; Pignataro G; Cicchetti A; Salomone S; Drago F
    Clin Drug Investig; 2016 Jul; 36(7):579-89. PubMed ID: 27153824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.
    Li BX; Wang YQ; Yi YY; Zhou N; Lv ZX; Ma R; Li X; Yuan N
    BMC Public Health; 2024 May; 24(1):1309. PubMed ID: 38745323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time.
    Saluja R; Arciero VS; Cheng S; McDonald E; Wong WWL; Cheung MC; Chan KKW
    J Oncol Pract; 2018 May; 14(5):e280-e294. PubMed ID: 29601250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018.
    Fu M; Naci H; Booth CM; Gyawali B; Cosgrove A; Toh S; Xu Z; Guan X; Ross-Degnan D; Wagner AK
    JAMA Intern Med; 2021 Dec; 181(12):1596-1604. PubMed ID: 34661604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
    Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD
    Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Access to innovative anticancer medicines in China: a national survey on availability, price and affordability.
    Li W; Lu W; Chen H; Zhang C; Wang M; Zheng F; Wu HH; Wan GW; Yang Q; Ye L
    BMJ Open; 2024 Apr; 14(4):e077089. PubMed ID: 38670605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
    Huang C; Ung COL; Wushouer H; Bai L; Huang T; Li X; Guan X; Shi L
    Health Res Policy Syst; 2022 Jan; 20(1):3. PubMed ID: 34980159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015.
    Grössmann N; Robausch M; Rothschedl E; Wild C; Simon J
    Eur J Cancer; 2020 Apr; 129():23-31. PubMed ID: 32120272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.
    Hill A; Redd C; Gotham D; Erbacher I; Meldrum J; Harada R
    BMJ Open; 2017 Jan; 7(1):e011965. PubMed ID: 28110283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of negotiated prices for new drugs in Germany.
    Gandjour A; Schüßler S; Hammerschmidt T; Dintsios CM
    Eur J Health Econ; 2020 Sep; 21(7):1049-1057. PubMed ID: 32451745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.